Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Operating Expenses (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Operating Expenses for 7 consecutive years, with $7.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Operating Expenses fell 28.0% to $7.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $42.1 million, a 19.0% decrease, with the full-year FY2024 number at $42.1 million, down 19.0% from a year prior.
  • Operating Expenses was $7.5 million for Q4 2024 at Actinium Pharmaceuticals, down from $12.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $15.6 million in Q2 2023 to a low of $5.3 million in Q2 2021.
  • A 4-year average of $9.7 million and a median of $9.7 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 98.13% in 2023, then decreased 28.0% in 2024.
  • Actinium Pharmaceuticals' Operating Expenses stood at $8.1 million in 2021, then surged by 39.9% to $11.3 million in 2022, then decreased by 7.68% to $10.4 million in 2023, then fell by 28.0% to $7.5 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Operating Expenses are $7.5 million (Q4 2024), $12.6 million (Q3 2024), and $12.4 million (Q2 2024).